Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259893 · ClinicalTrials.gov registry record · NA
Secondary Prevention of Atrial Fibrilation
A NA study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03259893 is a NA study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT03259893, a NA study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Atrial fibrillation (AF) is the most common arrhythmia affecting over 3 million Americans and about 33.5 million individuals globally. The lifetime risk of developing AF is 1 in 4 for adults over age 40 years. AF is associated with a major medical and socioeconomic burden including high cost, increased risk of stroke, heart failure, dementia, myocardial infarction, and death. Numerous studies have demonstrated that modifiable risk factors including hypertension, obesity, sleep apnea, diabetes, and sedentary lifestyle predict the development of AF. Recent studies have reported that secondary prevention interventions through aggressive risk factor modification can reduce the burden of AF. Structured, physician and nursing-led interdisciplinary AF programs have been shown to improve patient adherence to guideline recommendations and improve long term prognosis. Previous data, however, are derived mainly from white European and Australian cohorts and it is unclear whether such interventions can be effectively implemented in a racially diverse, safety net hospital in the U.S. This study is a randomized hybrid implementation-effectiveness study designed to investigate feasibility and effectiveness of an evidence-based innovative AF program, focusing on risk factor modification and AF education in a racially mixed population receiving care in a safety net hospital.
Interventions
- OTHER Standard of care
- OTHER AliveCor mobile ECG cardiac monitor
- BEHAVIORAL AF Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2020-05-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259893
The ClinicalTrials.gov registry entry for NCT03259893 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of care is the first listed.
NCT03259893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03259893 about?
NCT03259893 is a clinical study titled "Secondary Prevention of Atrial Fibrilation". Atrial fibrillation (AF) is the most common arrhythmia affecting over 3 million Americans and about 33.5 million individuals globally. The lifetime risk of developing AF is 1 in 4 for adults over age 40 years. AF is associated with a major medical and socioeconomic burden including high cost, increa...
What is the current status of trial NCT03259893?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2018-02-01. Estimated completion is 2020-05-11.
What interventions are being tested in trial NCT03259893?
The interventions under investigation include: Standard of care (OTHER), AliveCor mobile ECG cardiac monitor (OTHER), AF Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03259893?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.